Fig. 5

The correlation between the recurrence prediction score and clinical features. A Differences in wp-scores based on 11 5hmC biomarkers between recurrence and non-recurrence ESCC patients. B Distributions of risk scores, survival statuses, and hydroxymethylation modification level of the 11 genes. C Variations in prognostic outcomes based on the wd-score among ESCC patients. D-F Survival curves for ESCC patients categorized by the increased or decreased levels of hydroxymethylation modifications in LLPH, ANGPT2, and LINC02694, with the x-axis indicating OS time (months) and the y-axis depicting the probability of survival